Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amplify Cybersecurity ETF (HACK) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Amplify Cybersecurity ETFTrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Amplify Cybersecurity ETF vs Inovio Pharmaceuticals Inc — how do they compare? Amplify Cybersecurity ETF trades at $119.17, while Inovio Pharmaceuticals Inc trades at $0.79 (market cap $76.09M). The key difference: Amplify Cybersecurity ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

HACKINO
Sector
Sector/ThematicHealth
52-Week High
$119.19$2.87
52-Week Low
$70.69$0.66
Market Cap
$76.09M
Enterprise Value
$47.10M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amplify Cybersecurity ETF

HACK is trading at $115.42, up 1.97% with strong bullish momentum from moving averages. The ETF recently hit a 52-week high and is positioned to benefit from escalating cybersecurity spending, which is forecast to exceed $300 billion in 2026. Technical indicators show the stock is near resistance at $116 with RSI suggesting mild overbought conditions. Institutional interest is growing, with D.A. Davidson increasing its position by 44.8% in Q1 2026.

The outlook remains positive as AI-driven cyber threats fuel demand for cybersecurity solutions. Key risks include market volatility and competitive pressures from other cybersecurity ETFs. Analyst sentiment is bullish with the ETF capturing the full cybersecurity stack as enterprises increase digital defense budgets amid rising AI-powered threats.

Inovio Pharmaceuticals Inc

INO trades at $0.668, down 0.86% with bearish technical signals despite recent earnings beats. The company shows minimal revenue of $65,340 against substantial losses, with negative margins and cash flow challenges. Key catalyst is the FDA's October 2026 decision on INO-3107, while recent $20 million offering aims to fund operations.

High-risk biotech play with binary FDA outcome driving valuation. Analyst consensus is bullish (53% buy) with $3.25 price target, but fundamental weaknesses and litigation risks require caution. Success of INO-3107 is critical for turnaround, with current cash funding operations into early 2027.

Returns comparison

Trailing returns across standard periods

About Amplify Cybersecurity ETF

HACK provides diversified exposure to the global cybersecurity industry. It invests across the full value chain, including hardware, software, and consulting services, with key holdings in firms like Broadcom, Cisco, and Palo Alto Networks.

Read more on HACK

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO